Cancer-Associated Fibroblasts in breast cancer treatment response and metastasis.

Breast cancer (BrCa) is the leading cause of death among women worldwide, with about one million new cases diagnosed each year. In spite of the improvements in diagnosis, early detection and treatment, there is still a high incidence of mortality and failure to respond to current therapies. With the...

Descripción completa

Detalles Bibliográficos
Autores: Fernández Nogueira, Patricia, Fuster Orellana, Gemma, Gutierrez-Uzquiza, Álvaro, Gascón, Pere, Carbó Carbó, Neus, Bragado, Paloma
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/181124
Acceso en línea:https://hdl.handle.net/2445/181124
Access Level:acceso abierto
Palabra clave:Càncer de mama
Metàstasi
Fibroblasts
Breast cancer
Metastasis
id ES_22d5c56adb95ecb274c4d03d2a5a4e5b
oai_identifier_str oai:diposit.ub.edu:2445/181124
network_acronym_str ES
network_name_str España
repository_id_str
spelling Cancer-Associated Fibroblasts in breast cancer treatment response and metastasis.Fernández Nogueira, PatriciaFuster Orellana, GemmaGutierrez-Uzquiza, ÁlvaroGascón, PereCarbó Carbó, NeusBragado, PalomaCàncer de mamaMetàstasiFibroblastsBreast cancerMetastasisFibroblastsBreast cancer (BrCa) is the leading cause of death among women worldwide, with about one million new cases diagnosed each year. In spite of the improvements in diagnosis, early detection and treatment, there is still a high incidence of mortality and failure to respond to current therapies. With the use of several well-established biomarkers, such as hormone receptors and human epidermal growth factor receptor-2 (HER2), as well as genetic analysis, BrCa patients can be categorized into multiple subgroups: Luminal A, Luminal B, HER2-enriched, and Basal-like, with specific treatment strategies. Although chemotherapy and targeted therapies have greatly improved the survival of patients with BrCa, there is still a large number of patients who relapse or who fail to respond. The role of the tumor microenvironment in BrCa progression is becoming increasingly understood. Cancer-associated fibroblasts (CAFs) are the principal population of stromal cells in breast tumors. In this review, we discuss the current understanding of CAFs' role in altering the tumor response to therapeutic agents as well as in fostering metastasis in BrCa. In addition, we also review the available CAFs-directed molecular therapies and their potential implications for BrCa management.MDPI2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/181124Articles publicats en revistes (Bioquímica i Biomedicina Molecular)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.3390/cancers13133146Cancers, 2021, vol. 13, num. 13, p. 3146-3168https://doi.org/10.3390/cancers13133146cc-by (c) Fernàndez Nogueira, Patricia et al., 2021https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1811242026-05-27T06:46:51Z
dc.title.none.fl_str_mv Cancer-Associated Fibroblasts in breast cancer treatment response and metastasis.
title Cancer-Associated Fibroblasts in breast cancer treatment response and metastasis.
spellingShingle Cancer-Associated Fibroblasts in breast cancer treatment response and metastasis.
Fernández Nogueira, Patricia
Càncer de mama
Metàstasi
Fibroblasts
Breast cancer
Metastasis
Fibroblasts
title_short Cancer-Associated Fibroblasts in breast cancer treatment response and metastasis.
title_full Cancer-Associated Fibroblasts in breast cancer treatment response and metastasis.
title_fullStr Cancer-Associated Fibroblasts in breast cancer treatment response and metastasis.
title_full_unstemmed Cancer-Associated Fibroblasts in breast cancer treatment response and metastasis.
title_sort Cancer-Associated Fibroblasts in breast cancer treatment response and metastasis.
dc.creator.none.fl_str_mv Fernández Nogueira, Patricia
Fuster Orellana, Gemma
Gutierrez-Uzquiza, Álvaro
Gascón, Pere
Carbó Carbó, Neus
Bragado, Paloma
author Fernández Nogueira, Patricia
author_facet Fernández Nogueira, Patricia
Fuster Orellana, Gemma
Gutierrez-Uzquiza, Álvaro
Gascón, Pere
Carbó Carbó, Neus
Bragado, Paloma
author_role author
author2 Fuster Orellana, Gemma
Gutierrez-Uzquiza, Álvaro
Gascón, Pere
Carbó Carbó, Neus
Bragado, Paloma
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Càncer de mama
Metàstasi
Fibroblasts
Breast cancer
Metastasis
Fibroblasts
topic Càncer de mama
Metàstasi
Fibroblasts
Breast cancer
Metastasis
Fibroblasts
description Breast cancer (BrCa) is the leading cause of death among women worldwide, with about one million new cases diagnosed each year. In spite of the improvements in diagnosis, early detection and treatment, there is still a high incidence of mortality and failure to respond to current therapies. With the use of several well-established biomarkers, such as hormone receptors and human epidermal growth factor receptor-2 (HER2), as well as genetic analysis, BrCa patients can be categorized into multiple subgroups: Luminal A, Luminal B, HER2-enriched, and Basal-like, with specific treatment strategies. Although chemotherapy and targeted therapies have greatly improved the survival of patients with BrCa, there is still a large number of patients who relapse or who fail to respond. The role of the tumor microenvironment in BrCa progression is becoming increasingly understood. Cancer-associated fibroblasts (CAFs) are the principal population of stromal cells in breast tumors. In this review, we discuss the current understanding of CAFs' role in altering the tumor response to therapeutic agents as well as in fostering metastasis in BrCa. In addition, we also review the available CAFs-directed molecular therapies and their potential implications for BrCa management.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/181124
url https://hdl.handle.net/2445/181124
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.3390/cancers13133146
Cancers, 2021, vol. 13, num. 13, p. 3146-3168
https://doi.org/10.3390/cancers13133146
dc.rights.none.fl_str_mv cc-by (c) Fernàndez Nogueira, Patricia et al., 2021
https://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by (c) Fernàndez Nogueira, Patricia et al., 2021
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv Articles publicats en revistes (Bioquímica i Biomedicina Molecular)
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869404604703178752
score 15,300719

Similares en LA Referencia